Anavex Life Sciences Corp (AVXL)

[blu_1]

But if we are supposed to trust that transgenic mice are a reliable stand-in for humans when it comes to sigma 1 agonists and AD, by that logic, shouldn't we then be able to trust that they are reliable stand-ins for any drug that is intended to target some human cellular process? But does the data back that up? We know that there are other sigma 1 agonists that have been developed. Not exactly the same molecule as 2-73, but drugs that target sigma 1 nonetheless. Was there testing of those on transgenic mice in preclinical studies and how well did those results stack up against what was seen in human trials? These are the questions we should be asking.